The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007–2010†
Article first published online: 5 NOV 2012
Copyright © 2012 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 22, Issue 4, pages 335–344, April 2013
How to Cite
Greene, S. K., Li, L., Shay, D. K., Fry, A. M., Lee, G. M., Jacobsen, S. J., Baxter, R., Irving, S. A., Jackson, M. L., Naleway, A. L., Nordin, J. D., Narwaney, K. J. and Lieu, T. A. (2013), Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007–2010. Pharmacoepidem. Drug Safe., 22: 335–344. doi: 10.1002/pds.3363
- Issue published online: 1 APR 2013
- Article first published online: 5 NOV 2012
- Manuscript Accepted: 2 OCT 2012
- Manuscript Revised: 27 SEP 2012
- Manuscript Received: 18 JUL 2012
Additional supporting information may be found in the online version of this article.
Supplemental Table 1. Adverse event definitions for oseltamivir safety assessment.
Supplemental Table 2. Baseline patient characteristics before matching.
Supplemental Table 3. Diagnoses of patients with incident psychiatric events in the 1-7 day risk interval, by treatment status.
|pds_3363_supplementary_material.doc||Word document||206K||Supporting Information|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.